430 results on '"Radich, J."'
Search Results
2. Elevated CO2 Enhances Otolith Growth in Young Fish (Supplementary Data)
3. Pre- and post-transplant quantification of measurable (‘minimal’) residual disease via multiparameter flow cytometry in adult acute myeloid leukemia
4. Elevated CO₂ Enhances Otolith Growth in Young Fish
5. Biochemical reaction and diffusion in seafloor gas hydrate capillaries: Implications for gas hydrate stability
6. Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance
7. Mutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: a SWOG report
8. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study
9. Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study
10. Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value
11. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia
12. Absolute quantitative detection of ABL tyrosine kinase domain point mutations in chronic myeloid leukemia using a novel nanofluidic platform and mutation-specific PCR
13. Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia
14. Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase
15. BCR-ABL1-positive CML and BCR-ABL1-negative chronic myeloproliferative disorders: some common and contrasting features
16. Metalloenzymes
17. Metallothionein enzymes
18. Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia
19. Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML
20. A distinctive nuclear morphology in acute myeloid leukemia is strongly associated with loss of HLA-DR expression and FLT3 internal tandem duplication
21. P50 Using Biomarker Change and Treatment Adherence to Predict Risk of Relapse Among Chronic Myeloid Leukemia Patients Who Are in Remission
22. Predicting relapse prior to transplantation in chronic myeloid leukemia by integrating expert knowledge and expression data
23. Decreased IRF8 expression found in aging hematopoietic progenitor/stem cells
24. Isolation of CD34+ cells from blood stem cell components using the Baxter Isolex system
25. Seven year follow-up of the International Randomized Study of Interferon Versus STI571 (IRIS) demonstrates durable efficacy and long-term safety of imatinib in patients (pts) with newly diagnosed chronic myeloid leukaemia in chronic phase (CML-CP): 102
26. Children's behaviour : whose problem is it?
27. Syngeneic BMT for CML in chronic phase: update of the Seattle results
28. Graft-versus-leukemia effect in acute lymphoblastic leukemia: the importance of tumor burden and early detection
29. The detection and significance of minimal residual disease in acute and chronic leukemia
30. Fludarabine and targeted busulfan as conditioning for patients with high-risk chronic myelogenous leukemia and myelodysplastic syndrome transplanted with hematopoietic stem cells from HLA-compatible related or unrelated donors: 317
31. PF405 DASCERN 2-YEAR EXTENDED FOLLOW-UP OF DASATINIB EFFICACY AND SAFETY IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) WHO HAVE SUBOPTIMAL RESPONSES TO 3 MONTHS OF IMATINIB
32. The effect of long-term freezing of RT-PCR reagent mixes on the sensitivity of bcr-abl mRNA detection
33. Erratum: Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia
34. Erratum: Decreased IRF8 expression found in aging hematopoietic progenitor/stem cells
35. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet
36. Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale
37. UNA BASSA ESPRESSIONE DELLA FOSFATASI SHP-1 CORRELA CON LA RESI-STENZA AL TRATTAMENTO CON INIBITORI DELLE TIROSIN KINASI IN PAZIENTIAFFETTI DA LEUCEMIA MIELOIDE CRONICA
38. Association between transporters genotype and response to the treatment in a subset of previously untreated chronic myeloid leukemia patients enrolled into the tops trial
39. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study
40. Cost-Effectiveness of Personalized Treatment Switching Depending on Achievement of Early Molecular Response in Patients with Chronic Myeloid Leukemia
41. Chronic myeloid leukemia: Reminiscences and dreams
42. Chronic myeloid leukemia: reminiscences and dreams
43. Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale
44. Sequential Treatment of Chronic Myeloid Leukemia Patients: A Decision-analytic Cost-effectiveness Study
45. Choosing a Tyrosine Kinase Inhibitor as First-line Therapy for Chronic Myeloid Leukemia under the Uncertainty of Long-term Effectiveness and Safety
46. Advances in the biology and therapy of chronic myeloid leukemia (CML): Proceedings from the 6(th) Post-ASH International CML and Myeloproliferative Neoplasms Workshop
47. COST-EFFECTIVENESS ANALYSIS ON STARTING PATIENTS WITH CHRONIC MYELOID LEUKEMIA ON A HIGHLY POTENT TYROSINE KINASE INHIBITOR AND EARLY SWITCHING TO IMATINIB
48. Reduced Expression Level of SHP1 Gives An Additive Survival Advantage to the Ph plus Cells of Chronic Myeloid Leukemia (CML) Patients and Provides a Novel Pretreatment Predictor of Major Molecular Response Achievement in CML Patients
49. Elevated CO2 Enhances Otolith Growth in Young Fish (Supplementary Data)
50. A decreased Level of Shp1 provides an additive survival advantage to the Ph plus Cells of CML Patients and may account for Resistance to Imatinib Treatment
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.